The recent tremendous therapeutic success of highly selective CDK4/6 inhibitors against hormone-dependent metastatic breast cancers and their promising activity against other solid tumors (Schettini et al., 2018) have demonstrated that CDKs can be valuable therapeutic targets, provided that they are addressed by selective molecules. This evidence concerns the gene CDK4 and breast cancer.